The investigational SGLT2 inhibitor remogliflozin etabonate showed significant benefits for glucose control among patients with type 2 diabetes, a randomized study found.

The difference from placebo in hemoglobin (Hb) A1c at 12 weeks with 250 mg per day of remogliflozin was -0.56% (95% CI minus 0.95 to-minus 0.16, P=0.006), according to William O. Wilkison, PhD, of Islet Sciences in Raleigh, N.C., and colleagues.

In contrast, treatment with pioglitazone, 30 mg once daily, had a difference from placebo of minus 0.19% (95% CI minus 0.58-0.20, P=0.337), the researchers reported online in Diabetes, Obesity, and Metabolism.

Continue Reading

READ FULL ARTICLE Curated publisher From Medical Page Today